A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, open-label, non-randomized study in patients with locally advanced or
metastatic breast cancer.
Each cycle of treatment will be 4 weeks in length. Patients will be radiologically evaluated
every 8 weeks for response. Patients will continue to receive study treatment until disease
progression or unacceptable toxicity.